Fig. 4.

Hematopoietic CCRL2 is responsible for inhibiting melanoma growth in a CD8⁺ T cell–dependent manner. (A) Tumor growth curve. (B) Average percentages of different types of infiltrating immune cells in tumors of WT and Ccrl2^−/− mice on day 14. (C and D) CD4⁺ and CD8⁺ T cells were gated and examined for expression of Ki67 (C) and IFN-γ (D). (E) Expression of Granzyme B. (F) The concentrations of IFN-γ in tumor homogenates. (G) Expression of PD-1. (H–J) Tumor growth curve in bone marrow chimeras (H), WT and Ccrl2^−/− mice treated with neutralizing antibodies (Abs) against CD8 (I) or CD4 (J). Data represent mean ± SEM (n = 5 to 7). Similar results were obtained from three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant.